RT Journal Article
SR Electronic
T1 Predictive Role of CYFRA21-1 and CEA for Subsequent Docetaxel in Non-small Cell Lung Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5125
OP 5131
VO 37
IS 9
A1 KAZUKI SONE
A1 TETSUYA OGURI
A1 KEIMA ITO
A1 YUKI KITAMURA
A1 YOSHITSUGU INOUE
A1 AKIRA TAKEUCHI
A1 SATOSHI FUKUDA
A1 OSAMU TAKAKUWA
A1 KEN MAENO
A1 TAKAMITSU ASANO
A1 YOSHIHIRO KANEMITSU
A1 HIROTSUGU OHKUBO
A1 MASAYA TAKEMURA
A1 YUTAKA ITO
A1 AKIO NIIMI
YR 2017
UL http://ar.iiarjournals.org/content/37/9/5125.abstract
AB Background/Aim: The aim of the present study was to determine the clinical value of tumor marker levels for previously treated NSCLC patients. Patients and Methods: We retrospectively screened 113 previously treated patients with advanced NSCLC who were treated with docetaxel monotherapy regarding the pretreatment serum level of cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA). Results: The thirty-two patients with normal CYFRA21-1 levels and high CEA levels had a significantly higher response rate than the other 81 patients (25% vs. 8.6%, p=0.031). The former group showed statistically longer progression-free survival (PFS) and overall survival (OS) than the latter group (median PFS, 180 vs. 59 days, p<0.001; median OS, 579 vs. 255 days, p=0.002). In multivariate analysis, tumor marker levels had a significant impact on PFS and OS. Conclusion: Combination of the two tumor markers is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients.